In the human study reported by Kono et al. [3] , the increase in blood pressure to an intravenous infusion of des-aspartate-angiotensin I (DAA-I) was caused by angiotensin III, the immediate metabolite of DAA-I. The increase occurred within 2 min of the intravenous administration, indicating that DAA-I was rapidly degraded in the systemic circulation. When [ 14 C-Val 3 ]-DAA-I was incubated in a plasma sample, the degradation to angiotensin III, angiotensin IV and smaller fragments was a seamless process that lasted less than 3 min (unpublished data from a preclinical toxicology study). The oral bioavailability of DAA-I has been estimated to be 0.06 [4] . This low bioavailability together with its rapid degradation in the blood would indicate that orally administered DAA-I, like many endogenously produced compounds, does not have a canonical blood profile. Blood samplings at intervals of 2-3 min in the first 30 min post-DAA-I oral administration, as suggested by Dr. Srinivas, would approximate a continuous sampling, which is logistically difficult to execute and psychologically unfavourable to the volunteers. It also assumes that the peak plasma would be within the first 30 min post-DAA-I administration, which is not supported by preclinical data.
Incorporation of Angiotensin Receptor Blockers and Angiotensin Converting Enzyme Inhibitors
DAA-I (per se) has no effect on blood pressure [3] . We have also shown that orally administered DAA-I (up to a dose of 23.6 mg/kg) had no effect on the blood pressure in the rat (unpublished data from a preclinical toxicology study). Therefore, blood pressure, as suggested by Dr. Srinivas, would not be a suitable surrogate marker.
Angiotensin receptor blockers block the angiotensin AT 1 receptor and losartan has been shown to block the action of DAA-I [5, 6] . Hence, incorporation of an angiotensin receptor blocker or an angiotensin converting enzyme inhibitor in a proof-of-concept study, as suggested by Dr. Srinivas, would be incoherent. A definitive proof-of-concept study for DAA-I would be a phase IIa clinical trial on 24 patients with type 2 diabetes mellitus to establish its efficacy (effective glycaemic control). However, a phase IIa trial would have to be supported by safety data from a prior multi-dose phase I trial.
Surrogate Biomarker
The measurement of prostaglandin E 2 and or prostaglandin I 2 as surrogate biomarker/s of DAA-I is our preferred choice in tracking the biological action and bioavailability of DAA-I in a multi-dose phase I trial. Prostaglandin E 2 and prostaglandin I 2 have been associated with glycemic improvement of type 2 diabetes and its associated complications [7] [8] [9] . These two prostaglandins are therefore relevant surrogate biomarkers in our anticipated multi-dose phase I trial.
Angiotensin Peptide Drug
Angiotensin-(1-7) [10, 11] and TRV027 [12] are two other angiotensin peptides currently being developed as potential drugs. Like DAA-I, these two angiotensin peptides are biased agonists and exhibit specific therapeutic actions. However, unlike DAA-I they are not orally active and have to be given parenterally. The reason is because, unlike DAA-I, angiotensin-(1-7) and TRV027 are not effective at doses that are below the Km of peptidases. With this unique property, DAA-I is an investigator's dream drug. Doses above therapeutic levels that cause secondary biological actions or toxicities are rapidly brought down to physiological levels. Rapid internalisation of the bound DAA-I/angiotensin AT 1 receptor complex is reminiscent of drug-targeting therapy, especially when upregulation of the angiotensin AT 1 receptors is known to occur in DAA-Iresponsive diseases [13, 14] . The lack of a canonical plasma profile is only a problem to naive institutional regulators, and DAA-I is pharmacologically a safe drug to develop.
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